secwatch.observer — SEC 8-K summary
======================================

Issuer:     ONCOLYTICS BIOTECH INC (ONCY)
CIK:        0001129928
Form:       8-K
Filed at:   2026-10-14T13:33:28+00:00
Accession:  0001129928-26-000072
Event type: other_material
Sentiment:  positive
Materiality: 0.45
Item codes: 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Oncolytics sees final PanCAN grant payment this quarter; GOBLET Cohort 4 data due Q4 2026
--------------------------------------------------------------------------------

- Oncolytics (Nasdaq: ONCY) expects the final Pancreatic Cancer Action Network grant payment later this quarter after completing Cohort 5 wind-down activities.
- Final Cohort 4 results, testing pelareorep with atezolizumab in second-line or later squamous cell anal carcinoma, are expected in Q4 2026.
- Initial Cohort 5 results in first-line metastatic pancreatic ductal adenocarcinoma are expected in H1 2027, but could slip as patients stay on treatment.
- CMO Thomas Heineman said Cohort 4 median overall survival exceeds the company's expectations, with the full data set still being processed.
- Oncolytics said every GOBLET cohort that enrolled the required number of patients met its pre-specified efficacy success criteria.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1129928/000112992826000072/0001129928-26-000072-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1129928/000112992826000072/oncy-20261014.htm
  HTML page:      https://secwatch.observer/filing/0001129928-26-000072

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer